EUROPE – Ipsen, a French based company, has entered into collaboration with BAKX Therapeutics with an aim to focus on an oral small-molecule activator of BAX for the potential treatment of leukemia, lymphoma and solid tumors.
Under the terms of the deal, Ipsen will collaborate with BAKX Therapeutics to research, develop, manufacture and commercialize BKX-001 in these oncology indications.
BAX is a novel target in the apoptosis cell-signaling pathway apoptosis is the naturally occurring process of programmed cell death.
Global Immuno- oncology clinical trials market
Based on a report from Research and Markets, he global immuno-oncology clinical trials market size is expected to reach US$ 15.1 billion by 2028 and is expected to expand at a CAGR of 13.6% from 2021 to 2028.
The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.
From 2014 to 2017, the number of new immuno-oncology studies increased from 250 to almost 600, with double-digit growth rates each year as drug classes diversified.
Biomarker and checkpoint inhibitor studies were primarily responsible for this rapid growth. While the immuno-oncology market is maturing in some pharmacological classes, cell therapies are exceeding all other immunotherapeutic in terms of growth.
In March 2020, there were 1,483 active compounds in the pipeline for cancer cell therapy globally, indicating an increase of 472 from March 2019.
The fastest-growing category was chimeric antigen receptor T (CAR-T) cell products (up 77% from 2019 to 2020).
Besides, during the Covid-19 pandemic, the number of Immuno-Oncology drugs in development increased from 3,876 in 2019 to 4,720 in 2020, representing a 22% & 233% increase as compared to 2019 & 2017 respectively.
After a moderate increase of 15% in 2019 compared to 68% between 2018 and 2017, this 22% increase indicates a return of interest in Immuno- Oncology, despite the impact of the COVID-19 pandemic.
Phase III dominated the market with the largest share of 53.2% in 2020. In 2019, 29.0% of Phase III drugs have a higher-than-average chance of approval, up from 24.2% in 2018 with the interventional experiments accounting for more than 78.6% of the market share in 2020.
The segment of solid tumors held 56.0% of the revenue share in 2020 and was largely attributed to the rise in the prevalence of solid tumors.
North America dominated the market and accounted for the largest revenue share of 51.0% in 2020 and was due to the rising adoption of personalized medicine-focused novel treatment methods, as well as the government funding and investments.
Asia Pacific is expected to register the fastest growth rate of 14.7% over the forecast period. As at the end of 2019, over 40.0% of current immuno-oncology clinical experiments involved at least one location in the region.
Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE